Many of the medications used to treat COVID-19 in more severe cases require IV infusion, are expensive, and are usually reserved for hospitalized patients or specialized centres providing treatment for those at the highest risk of severe outcomes.
COVID-19 vaccines have helped to reduce infection severity in Canada and around the world. As a result, patients with mild to moderate symptoms are now going to their primary care providers, including family doctors, walk-in clinics, and other community care settings, for access to care for COVID-19.
Although their symptoms may not be as severe, some patients can still be at risk of hospitalization, death, or developing long COVID. It is urgent that we identify effective, safe, affordable, and evidence-based medications so they can be accessed by the community, reducing the burden on hospitals and ICUs. The long-term goal for this study is to find which medications work best to reduce hospitalizations and death and help people feel better faster.